SCHEMBL25324441

SCHEMBL25324441

O=C(N1CC2(CC(c3nnc(C4CCC4)[nH]3)C2)C1)N1CC2(C1)CN(S(=O)(=O)c1cccc(OC(F)(F)F)c1)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 1/20 0.42
▸ MGLL Q99685 2/20 0.41
▸ ABHD6 Q9BV23 1/20 0.41
▸ SCN9A Q15858 1/20 0.38
▸ KDM2B Q8NHM5 1/20 0.36
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ BCL9 O00512 2/20 0.35
▸ CTNNB1 P35222 2/20 0.35
▸ CYP11B1 P15538 1/20 0.35
▸ CYP11B2 P19099 1/20 0.35
▸ RORC P51449 1/20 0.35
▸ CACNA1B Q00975 2/20 0.34
▸ HRH3 Q9Y5N1 2/20 0.34
▸ LIPE Q05469 1/20 0.34
▸ HCRTR1 O43613 1/20 0.34
▸ HCRTR2 O43614 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25327398 0.97 AKR1C3 (0.44) AKR1C3MGLLABHD6SCN9AKDM2B
SCHEMBL25323642 0.90 MEN1 (0.43) AKR1C3SCN9AKMT2AMEN1LIPE
SCHEMBL25324983 0.88 AKR1C3 (0.39) AKR1C3MGLLABHD6SCN9AKDM2B
SCHEMBL25325330 0.86 DPP4 (0.42) AKR1C3KMT2AMEN1LIPE
SCHEMBL25325495 0.85 MGLL (0.40) AKR1C3MGLLABHD6SCN9AKDM2B
SCHEMBL25326299 0.84 CNR1 (0.46) AKR1C3KMT2AMEN1CACNA1BLMNA
SCHEMBL25324840 0.82 HDAC8 (0.43) AKR1C3MGLLABHD6LIPE
SCHEMBL25324806 0.81 KIT (0.43) AKR1C3MGLLABHD6
SCHEMBL25322792 0.79 AKR1C3 (0.42) AKR1C3MGLLABHD6KDM2BRORC
SCHEMBL30700725 0.79 AKR1C3 (0.46) AKR1C3MGLLABHD6SCN9AKDM2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US claimed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP claimed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO claimed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US disclosed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP disclosed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 AKR1C3 257/4885MGLL 3523/4885ABHD6 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback